Biomarkers in breast cancer - An update;Biomarker beim Mammakarzinom - ein Update

Geburtshilfe und Frauenheilkunde

Volumn 72, Issue 9, 2012, Pages 819-832

  Schmidt, M ^a   Fasching, P A ^b   Beckmann, M W ^b   Kolbl H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

biomarker; breast cancer; Her2 neu (human epidermal growth factor receptor)

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MOLECULAR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MATHEMATICAL MODEL; PREDICTION; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; VALIDATION PROCESS;

EID: 84866562906     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0032-1315340     Document Type: Review

References (77)

1. Peto R., Boreham J., Clarke M. et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 2069 years. Lancet: 2000; 355 1822 10.1016/S0140-6736(00)02277-7 (Pubitemid 30265099)
2. Berry D. A., Cronin K. A., Plevritis S. K. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med: 2005; 353 1784 1792 10.1056/NEJMoa050518 (Pubitemid 41549890)
3. Fasching P. A., Fehm T., Janni W. et al. Breast cancer therapy a state of the art review. Geburtsh Frauenheilk: 2010; 70 875 886 10.1055/s-0030-1250437
4. Kummel S., Kolberg H. C., Luftner D. et al. Breast cancer 2011 new aspects. Geburtsh Frauenheilk: 2011; 71 939 953 10.1055/s-0031-1280313
5. Goldhirsch A., Coates A. S., Gelber R. D. et al. First select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol: 2006; 17 1772 1776 10.1093/annonc/mdl398 (Pubitemid 44884051)
6. Liedtke C., Wolf M. K., Kiesel L. New concepts for targeted systemic therapy in breast cancer. Geburtsh Frauenheilk: 2010; 70 625 633 10.1055/s-0030-1250182
7. Peto R., Davies C., Godwin J. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials. Lancet: 2012; 379 432 444 10.1016/S0140-6736(11)61625-5
8. Goldhirsch A., Wood W. C., Coates A. S. et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol: 2011; 22 1736 1747 10.1093/annonc/mdr304
9. Untch M., Gerber B., Mobus V. et al. Zurich Consensus: statement of German experts on St. Gallen conference 2011 on breast cancer (Zurich 2011). Geburtsh Frauenheilk: 2011; 71 381 390 10.1055/s-0030-1271133
10. Ravdin P. M., Siminoff L. A., Davis G. J. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol: 2001; 19 980 991 (Pubitemid 32176272)
11. Olivotto I. A., Bajdik C. D., Ravdin P. M. et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol: 2005; 23 2716 2725 10.1200/JCO.2005.06.178 (Pubitemid 46179461)
12. Mook S., Schmidt M. K., Rutgers E. J. et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol: 2009; 10 1070 1076 10.1016/S1470-2045(09)70254-2
13. Ozanne E. M., Braithwaite D., Sepucha K. et al. Sensitivity to input variability of the Adjuvant! online breast cancer prognostic model. J Clin Oncol: 2009; 27 214 219 10.1200/JCO.2008.17.3914
14. Schmidt M., Victor A., Bratzel D. et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol: 2009; 20 258 264
15. Wishart G. C., Bajdik C. D., Dicks E. et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer: 2012; 10.1038/bjc.2012.338
16. Wishart G. C., Bajdik C. D., Azzato E. M. et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol: 2011; 37 411 417 10.1016/j.ejso.2011.02.001
17. Wishart G. C., Azzato E. M., Greenberg D. C. et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res: 2010; 12 R1 10.1186/bcr2464
18. Jung S. Y., Han W., Lee J. W. et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! online risk categories in early breast cancer. Ann Surg Oncol: 2009; 16 1112 1121 10.1245/s10434-009- 0334-7
19. Viale G., Regan M. M., Mastropasqua M. G. et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst: 2008; 100 207 212 10.1093/jnci/djm289 (Pubitemid 351480546)
20. Urruticoechea A., Smith I. E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol: 2005; 23 7212 7220 10.1200/JCO.2005.07.501
21. Cheang M. C., Chia S. K., Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst: 2009; 101 736 750 10.1093/jnci/djp082
22. Hammond M. E., Hayes D. F., Dowsett M. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol: 2010; 28 2784 2795 10.1200/JCO.2009.25.6529
23. Wolff A. C., Hammond M. E., Schwartz J. N. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol: 2007; 25 118 145 10.1200/JCO.2006.09.2775 (Pubitemid 350003059)
24. Dowsett M., Nielsen T. O., AHern R. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst: 2011; 103 1656 1664 10.1093/jnci/djr393
25. McShane L. M., Altman D. G., Sauerbrei W. et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol: 2005; 23 9067 9072 10.1200/JCO.2004.01.0454
26. Hayes D. F., Bast R. C., Desch C. E. et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst: 1996; 88 1456 1466 (Pubitemid 26340047)
27. Simon R. M., Paik S., Hayes D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst: 2009; 101 1446 1452 10.1093/jnci/djp335
28. Harris L., Fritsche H., Mennel R. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol: 2007; 25 5287 5312 10.1200/JCO.2007.14.2364 (Pubitemid 350232263)
29. Janicke F., Schmitt M., Pache L. et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat: 1993; 24 195 208 (Pubitemid 23062819)
30. Look M. P., van Putten W. L., Duffy M. J. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst: 2002; 94 116 128 (Pubitemid 34121291)
31. Janicke F., Prechtl A., Thomssen C. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst: 2001; 93 913 920 (Pubitemid 32624648)
32. Thomssen C., Harbeck N., Dittmer J. et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J Natl Cancer Inst: 2009; 101 1028 1029 10.1093/jnci/djp145
33. Strehl J. D., Wachter D. L., Fasching P. A. et al. Invasive breast cancer: recognition of molecular subtypes. Breast Care (Basel): 2011; 6 258 264 10.1159/000331339
34. Sorlie T., Perou C. M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA: 2001; 98 10869 10874 10.1073/pnas.191367098 (Pubitemid 32878711)
35. Smid M., Wang Y., Zhang Y. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res: 2008; 68 3108 3114 10.1158/0008-5472.CAN-07-5644
36. Rouzier R., Perou C. M., Symmans W. F. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res: 2005; 11 5678 5685 10.1158/1078-0432.CCR-04-2421 (Pubitemid 41170290)
37. Parker J. S., Mullins M., Cheang M. C. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol: 2009; 27 1160 1167 10.1200/JCO.2008.18.1370
38. Mackay A., Weigelt B., Grigoriadis A. et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst: 2011; 103 662 673 10.1093/jnci/djr071
39. Haibe-Kains B., Desmedt C., Loi S. et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst: 2012; 104 311 325 10.1093/jnci/djr545
40. vant Veer L. J., Dai H., van de Vijver M. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature: 2002; 415 530 536 10.1038/415530a (Pubitemid 34130608)
41. van de Vijver M. J., He Y. D., vant Veer L. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med: 2002; 347 1999 2009 10.1056/NEJMoa021967 (Pubitemid 35461656)
42. Buyse M., Loi S., vant Veer L. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst: 2006; 98 1183 1192 10.1093/jnci/djj329 (Pubitemid 44390989)
43. Cardoso F., vant Veer L., Rutgers E. et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol: 2008; 26 729 735 10.1200/JCO.2007.14.3222 (Pubitemid 351264385)
44. Paik S., Shak S., Tang G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med: 2004; 351 2817 2826 10.1056/NEJMoa041588 (Pubitemid 40051905)
45. Paik S., Tang G., Shak S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol: 2006; 24 3726 3734 10.1200/JCO.2005.04.7985 (Pubitemid 46622311)
46. Albain K. S., Barlow W. E., Shak S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol: 2010; 11 55 65 10.1016/S1470-2045(09)70314-6
47. Sparano J. A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol: 2008; 26 721 728 10.1200/JCO.2007.15.1068 (Pubitemid 351264384)
48. Filipits M., Rudas M., Jakesz R. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res: 2011; 17 6012 6020 10.1158/1078-0432.CCR-11-0926
49. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med: 2009; 360 790 800 10.1056/NEJMra0801289
50. Fan C., Oh D. S., Wessels L. et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med: 2006; 355 560 569 10.1056/NEJMoa052933 (Pubitemid 44200649)
51. Reis-Filho J. S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet: 2011; 378 1812 1823 10.1016/S0140-6736(11)61539-0
52. Rody A., Holtrich U., Pusztai L. et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res: 2009; 11 R15 10.1186/bcr2234
53. Teschendorff A. E., Miremadi A., Pinder S. E. et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol: 2007; 8 R157 10.1186/gb-2007-8-8-r157 (Pubitemid 351891480)
54. Alexe G., Dalgin G. S., Scanfeld D. et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res: 2007; 67 10669 10676 10.1158/0008-5472.CAN-07-0539 (Pubitemid 350145892)
55. Schmidt M., Bohm D., von Torne C. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res: 2008; 68 5405 5413 10.1158/0008-5472.CAN-07-5206
56. Schmidt M., Hellwig B., Hammad S. et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res: 2012; 18 2695 2703 10.1158/1078-0432.CCR-11-2210
57. Schmidt M., Hengstler J. G., von Torne C. et al. Coordinates in the universe of node-negative breast cancer revisited. Cancer Res: 2009; 69 2695 2698 10.1158/0008-5472.CAN-08-4013
58. Russnes H. G., Navin N., Hicks J. et al. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest: 2011; 121 3810 3818 10.1172/JCI57088
59. Curtis C., Shah S. P., Chin S. F. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature: 2012; 486 346 352 10.1038/nature10983
60. Perou C. M., Sorlie T., Eisen M. B. et al. Molecular portraits of human breast tumours. Nature: 2000; 406 747 752 10.1038/35021093
61. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet: 2005; 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
62. Colleoni M., Viale G., Zahrieh D. et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res: 2004; 10 6622 6628 10.1158/1078-0432.CCR-04-0380 (Pubitemid 39346559)
63. Slamon D. J., Clark G. M., Wong S. G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science: 1987; 235 177 182 (Pubitemid 17231334)
64. Ross J. S., Slodkowska E. A., Symmans W. F. et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist: 2009; 14 320 368 10.1634/theoncologist.2008-0230
65. De Laurentiis M., Arpino G., Massarelli E. et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res: 2005; 11 4741 4748 10.1158/1078-0432. CCR-04-2569 (Pubitemid 41557193)
66. Pritchard K. I., Shepherd L. E., OMalley F. P. et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med: 2006; 354 2103 2111 10.1056/NEJMoa054504 (Pubitemid 43736610)
67. Hayes D. F., Thor A. D., Dressler L. G. et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med: 2007; 357 1496 1506 10.1056/NEJMoa071167 (Pubitemid 47572635)
68. Slamon D. J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med: 2001; 344 783 792 10.1056/NEJM200103153441101 (Pubitemid 32222155)
69. Dawood S., Broglio K., Buzdar A. U. et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol: 2010; 28 92 98 10.1200/JCO.2008.19. 9844
70. Petit T., Wilt M., Velten M. et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer: 2004; 40 205 211 (Pubitemid 38077022)
71. Fasching P. A., Heusinger K., Haeberle L. et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC cancer: 2011; 11 486 10.1186/1471-2407-11-486
72. Chang J., Powles T. J., Allred D. C. et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res: 2000; 6 616 621 (Pubitemid 30111487)
73. Viale G., Giobbie-Hurder A., Regan M. M. et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 198 comparing adjuvant tamoxifen with letrozole. J Clin Oncol: 2008; 26 5569 5575 10.1200/JCO.2008.17.0829
74. Bartlett J. M., Munro A., Cameron D. A. et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol: 2008; 26 5027 5035 10.1200/JCO.2007.14.6597
75. Knoop A. S., Knudsen H., Balslev E. et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol: 2005; 23 7483 7490 10.1200/JCO.2005.11. 007 (Pubitemid 46291811)
76. Bartlett J. M., Munro A. F., Dunn J. A. et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol: 2010; 11 266 274 10.1016/S1470-2045(10)70006-1
77. Brase J. C., Schmidt M., Fischbach T. et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res: 2010; 16 2391 2401 10.1158/1078-0432.CCR-09-2471